Predictive value of serum caspase-cleaved @entity2873 concentrations after acute XXXX .

@entity1 @entity64 @entity3124 @entity2873 @entity1410 @entity1779
BACKGROUND: Caspase-cleaved @entity2873 (CCCK-18) is released during apoptosis. Serum CCCK-18 concentrations are associated with prognosis of some @entity3124 . We investigated the potential relationships between serum CCCK-18 concentrations and disease severity and long-term clinical outcomes after @entity1779 . METHODS: Serum CCCK-18 concentrations were determined in a total of 102 @entity1 and 102 controls. Multivariate models were used to predict high concentration of CCCK-18 and 6-month clinical outcomes. The predictive values were evaluated based on areas under receiver operating curve. RESULTS: Compared with controls, serum CCCK-18 concentrations were increased in @entity1 (245.8  108.3U/l vs. 23.6  18.1U/l, P<0.001). National Institute of Health @entity64 Scale scores [odds ratio (OR), 1.164; 95% confidence interval (CI), 1.027-1.320; P=0.003] and @entity1410 volumes (OR, 1.079; 95% CI, 1.018-1.205; P=0.008) were independent predictors of high concentration of CCCK-18. CCCK-18 was identified as an independent predictor of 6-month mortality (OR, 1.019; 95% CI, 1.010-1.038; P=0.013) and 6-month unfavorable outcome (OR, 1.017; 95% CI, 1.008-1.029; P=0.032) and possessed high predictive values. CONCLUSION: Increased serum CCCK-18 concentrations are associated with disease severity and clinical outcomes, suggesting that CCCK represent a novel prognostic predictive biomarker after @entity1779 .
